Nanostics Inc., a diagnostic healthcare company that focuses on developing tests to determine a patient's disease risk, announced today plans to develop and validate ClarityDX COVID-19; a simple blood test to predict the severity of COVID-19 disease in patients.
Nanostics, in collaboration with the Canadian BioSample Repository (CBSR) at the University of Alberta and Century Clinical Research Institute (CCRI), a Florida based clinical research company experienced at clinical study recruitment, will be collecting patient samples in Canada and the USA.
Nanostics' ClarityDX Platform technology will be used to accurately measure viral load along with other known immunological COVID-19 severity risk factors. The resulting blood test will use machine learning algorithms to determine the risk level of COVID-19 patients.
As countries rapidly increase their testing capabilities to be able to detect COVID-19 infected people, there remains a major unmet clinical need to determine which patients are at risk of developing severe COVID-19 outcomes and which patients will have mild symptoms. Nanostics' ClarityDX COV ID-19 test is designed to address this need.
The COVID-19 pandemic is unprecedented, approximately 20% of the people infected with SARS-CoV-2 become critically ill and many of those people die from this disease. We're joining the fight against COVID-19 by using our ClarityDX technology to rapidly and accurately predict which COVID-19 patients are at risk for developing severe disease."
John Lewis, CEO, Nanostics
ClarityDX COVID-19 is expected to play a significant role in helping healthcare professionals rapidly identify which patients are most at-risk of developing severe COVID-19 disease. This novel test will provide physicians with a better tool to manage the care of COVID-19 patient and improve patient outcomes.
Masks and smart seating cut COVID-19 risks on flights, review finds